Breaking News

Argentina Didn't Reach an Agreement With Holdouts: Mediator

Aoxing Pharmaceutical Company, Inc. Announces Receipt Of Production License For Pholcodine

 Aoxing Pharmaceutical Company, Inc. Announces Receipt Of Production License
                                For Pholcodine

PR Newswire

JERSEY CITY, N.J., Jan. 28, 2013

JERSEY CITY,N.J., Jan. 28, 2013 /PRNewswire/ -- Aoxing Pharmaceutical
Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical
company focusing on research, development, manufacturing, and distribution of
narcotic, pain-management, and addiction treatment pharmaceuticals, today
announced that its Chinese subsidiary has received from the State Food and
Drug Administration of China ("SFDA") a license to produce the active
pharmaceutical ingredient ("API") in Pholcodine. The company has commenced
preparation for the government's Good Manufacturing Practices (GMP)
inspection, which is the last regulatory hurdle before the company can take
the product to market in China.

Mrs. Guirong Zhou, Vice President for R&D, commented: "Our receipt of this
license is evidence of the quality of our research and development team. We
currently have a number of other products that have completed clinical trials
and are in the process of applying for the SFDA production license. Our
success in obtaining a production license for the Pholcodine API bodes well
for success in our future applications."

About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty
pharmaceutical company with its operations in China, specializing in research,
development, manufacturing and distribution of a variety of narcotics and
pain-management products. Headquartered in Shijiazhuang City, outside Beijing,
Aoxing has the largest and most advanced manufacturing facility in China for
highly regulated narcotic medicines. Its facility is one of the few GMP
facilities licensed for the manufacture of narcotic medicines by the China
State Food and Drug Administration (SFDA). It has a joint venture
collaboration with Johnson Matthey Plc to produce and market narcotics and
neurological drugs in China. For more information, please visit:

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements involve risks and uncertainties that may cause actual
results to differ materially from those set forth in these statements. All
forward-looking statements included herein are based upon information
available to the Company as of the date hereof and, except as is expressly
required by the federal securities laws, the Company undertakes no obligation
to update or revise any forward-looking statements, whether as a result of new
information, changed circumstances or future events or for any other reason.
To the extent that any statements made here are not historical, these
statements are essentially forward-looking. The Company uses words and phrases
such as "guidance," "forecasted," "projects," "is expected," "remain
confident," "will" and/or similar expressions to identify forward-looking
statements in this press release. Undue reliance should not be placed on
forward-looking information. The economic, competitive, governmental,
technological and other risk factors identified in the Company's filings with
the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors,"
in the Form 10-K for the year ended June 30, 2012, may cause actual results or
events to differ materially from those described in the forward looking
statements in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether because of
new information, future events, or otherwise.

Aoxing Pharmaceutical Company:

SOURCE Aoxing Pharmaceutical Company, Inc.